TORONTO, June 18 (Reuters) - Theratechnologies Inc said on Wednesday it received positive results in the confirmatory phase 3 trial of its lead compound tesamorelin to treat the increase of central fat accumulation in HIV-infected patients.
TORONTO, June 18 (Reuters) - Theratechnologies Inc said on Wednesday it received positive results in the confirmatory phase 3 trial of its lead compound tesamorelin to treat the increase of central fat accumulation in HIV-infected patients.
